20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
Globe Newswire•29/09/2026•08:31 ET
2
Key Highlights
- ➤FDA panel voted favorably on GRAIL’s Galleri MCED blood test’s safety, effectiveness, and benefit-risk profile
- ➤20/20 BioLabs (AIDX) targets Medicare reimbursement for MCED by the end of 2028
- ➤OneTest™ franchise lets regional laboratories offer tests while 20/20 retains models, patents, and biomarker data
- ➤Laboratories across the United States have shown preliminary interest in the OneTest™ franchise model
- ➤Webinar scheduled October 7, 2026, to discuss MCED regulation, reimbursement, and commercial expansion
Expert Statements
Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs
“The September 23 advisory committee meeting concerned another company’s test, but we believe many of the questions considered by the panel are relevant to multi-cancer early detection as a broader category.”
Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs
“On October 7, I look forward to discussing what we believe the meeting may indicate about the regulatory path for MCED tests, where OneTest™ stands today, and how our new franchise model and growing firefighter screening programs could expand access to early cancer detection.”
President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening
Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open
Get started
Create a free account to read the full story.